You are here

Genentech Asthma Drug Less Than Stellar in Late-Stage Studies

Clinical studies in other diseases ongoing

Genentech has announced the results from two phase 3 studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma. In the LAVOLTA I trial, lebrikizumab reduced asthma exacerbations and improved lung function, but not as significantly as in its phase 2 trials. In the LAVOLTA II trial, lebrikizumab failed to produce statistically significant results for either endpoint, BioSpace reports.

LAVOLTA I and II included more than 2,100 people across 28 countries with severe asthma that was uncontrolled despite treatment with an inhaled corticosteroid and a second controller medication. The two identical, randomized, multicenter, placebo-controlled phase 3 studies had the primary endpoint of reducing the rate of asthma exacerbations over 52 weeks. The secondary endpoint of both was improvement in lung function as measured by forced expiratory volume in one second. Each of the endpoints was based on a subgroup of people with higher levels of serum periostin (a protein identified as a key biomarker of inflammation in certain types of asthma) or blood eosinophils (inflammatory cells sometimes present in increased numbers in the airways and blood of people with asthma).

 “We were hopeful these identical studies would confirm the phase 2 results because there is still a significant unmet need for people with severe asthma,” said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. “These data require further interpretation, and analyses are ongoing to better understand the results and determine next steps.”

Lebrikizumab, a novel humanized monoclonal antibody, is designed to specifically block the action of the cytokine interleukin-13 (IL-13), a key contributor to airway inflammation and asthma in some patients. Ongoing clinical studies of the drug are being conducted in asthma, chronic obstructive pulmonary disease, atopic dermatitis, and idiopathic pulmonary fibrosis.

Source: BioSpace; February 29, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs